Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases

  title={Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases},
  author={Satoshi Tanida and Tsutomu Mizoshita and Hirotada Nishie and Keiji Ozeki and Takahito Katano and Takaya Shimura and Eiji Kubota and Hiromi Kataoka and Takeshi Kamiya and Takashi Joh},
  journal={Journal of Clinical Medicine Research},
  pages={334 - 337}
The long-term efficacy and safety of adalimumab (ADA) for the treatment of intestinal Behcet’s disease (BD) in the clinical setting have not been evaluated previously. This retrospective study evaluated the 52-week efficacy of ADA in BD patients. A total of eight patients who were refractory to conventional therapy were given ADA (160/80/40 mg every other week). Marked improvement (MI) was achieved by 10 weeks in five patients (62.5%), and by 52 weeks in six patients (75%). In addition… Expand

Figures, Tables, and Topics from this paper

Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
This large real-world study confirmed the long-term safety and effectiveness of adalimumab in patients with intestinal Behçet’s disease. Expand
Management of severe complications in Behçet’s disease with TNF inhibitors
The currently available efficacy and safety data of anti-TNFα agents in BD are summarized to properly evaluate their efficacy as first line therapeutic in life-threatening manifestations of BD. Expand
Updated treatment strategies for intestinal Behçet’s disease
The current therapeutic strategies and new clinical data for the treatment of intestinal BD are reviewed and new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Expand
Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
Agents such as golimumab, etanercept, and certolizumab pegol are described, which have recently been shown to be effective in refractory intestinal Behçet’s disease, including vulnerability to infections and malignancy. Expand
Update on the Medical Management of Gastrointestinal Behçet's Disease
This work provides a digest of all current experience and evidence about pharmacological agents suggested by the medical literature as having a potential role for managing the dreadful features of GIBD. Expand
One year in review 2016: Behçet's syndrome.
Several articles highlighting the epidemiology, pathogenesis, clinical features, treatment modalities and disease assessment of Behçet's syndrome (BS) have been published during the last year.Expand
Gr upSM Treatment of Systemic Involvement of Behçet ’ s Disease
Behçet’s disease (BD) is a multi genetic, chronic systemic vasculitis with an unknown origin characterized by recurrent oral ulcers, mucocutaneus disorders and ocular findings, as well as articular,Expand


Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
IFX is effective and safe in patients with refractory intestinal BD, and a response to IFX was maintained in seven of the 11 patients available at 12 months and in four of the eight patients Available at 24 months. Expand
Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
  • S. Tanida, N. Inoue, +15 authors T. Hibi
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2015
Adalimumab is a potentially effective treatment for intestinal Behçet's disease in Japanese patients who are refractory to conventional treatments. Expand
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks. Expand
Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.
Infliximab treatment for Behçet disease uveoretinitis was well tolerated, with nonserious adverse effects occurring in about half of the patients, accompanied by improvement in the mean visual acuity. Expand
Long-Term Clinical Outcomes and Factors Predictive of Relapse After 5-Aminosalicylate or Sulfasalazine Therapy in Patients With Intestinal Behcet Disease
5-ASA/sulfasalazine therapy has a positive effect in maintaining remission in patients with intestinal BD, however, a younger age (<35 y), higher C-reactive protein level (≥1.5 mg/dL), and a higher disease activity index for intestinal Behcet disease score (≤60) were associated with a poor response to 5- ASA/ sulfasAlazine therapy, making careful observation and intensive treatment necessary in these risk groups. Expand
Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.
There is enough published experience to suggest that TNF blockade represents an important therapeutic advancement for patients with severe and resistant, or intolerant, to standard immunosuppressive regimens BD. Expand
Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease.
This case report suggests the effectiveness of adalimumab as first anti-TNFα in case of steroid-dependent/resistant gastrointestinal BD. Expand
Cytokine production profile in patients with Behcet's disease treated with infliximab.
It is indicated that TNF-alpha plays a pivotal role in Behcet's disease, and that anti-TNF- alpha therapy both reduces T NF-alpha production and modulates the functional activity of type 1 cells. Expand
Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.
It is suggested that infliximab may be an effective new therapy for gastrointestinal BD, and perhaps other manifestations of BD as well. Expand
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFa monoclonal antibodies
Improved clinical statements regarding indications for anti-TNFa mAbs use were developed and after a two-round modified Delphi approach, the second edition of consensus statements was finalized. Expand